
# **Spiropentanes**


#### Introduction

The spiropentyl substituent has gained traction in recent medicinal chemistry projects, not only for its elegant, bow-tie-like appearance but also for its highly desirable 3D structure. 1.2 Recent studies from Merck demonstrate that this fragment enhances local hydrophobicity while resisting metabolic clearance - favorable traits for improving a drug's pharmacokinetic profile.3.4 In July 2024, Vertex submitted a new drug application to the FDA for vanzacaftor, a molecule featuring the spiropentyl group, aimed at treating cystic fibrosis. Enamine offers an extensive selection of molecular building blocks with small spiro skeletons, spiropentane and dispiroheptane.




Vanzacaftor (VX-121) Phase 3 trials against cystic fibrosis

Vertex Pharm




Ras protein inhibitor, anticancer WO 2024/081363



Polymerase theta inhibitor, radiotherapy WO 2024/069592

## Case study

selective brain penetrant inhibitor of leucine-rich repeat kinase 2




J. Med. Chem. 2022, 65, 16801




serine-threonine protein kinase with the ligand (grey)

conformation:





## We offer: over 50 spiropentanes from stock on 5-10 gram scale.



#### **References**

- K. Zhang et al. J. Med. Chem. 2023, 66, 4378.
   R. Sabnis and A. Sabnis. ACS Med. Chem. Lett. 2023, 14, 698.
- 3. K. Candito et al. *J. Med. Chem.* **2022**, *65*, 16801. 4. S. Kattar et al. *J. Med. Chem.* **2023**, *66*, 14912.



